1CE7
MISTLETOE LECTIN I FROM VISCUM ALBUM
Summary for 1CE7
Entry DOI | 10.2210/pdb1ce7/pdb |
Descriptor | PROTEIN (RIBOSOME-INACTIVATING PROTEIN TYPE II), 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total) |
Functional Keywords | ribosome-inactivating protein type ii, ribosome |
Biological source | Viscum album (European mistletoe) More |
Total number of polymer chains | 2 |
Total formula weight | 53473.56 |
Authors | Krauspenhaar, R.,Eschenburg, S.,Perbandt, M.,Kornilov, V.,Konareva, N.,Mikailova, I.,Stoeva, S.,Wacker, R.,Maier, T.,Singh, T.P.,Mikhailov, A.,Voelter, W.,Betzel, C. (deposition date: 1999-03-18, release date: 2000-03-20, Last modification date: 2023-08-09) |
Primary citation | Krauspenhaar, R.,Eschenburg, S.,Perbandt, M.,Kornilov, V.,Konareva, N.,Mikailova, I.,Stoeva, S.,Wacker, R.,Maier, T.,Singh, T.P.,Mikhailov, A.,Voelter, W.,Betzel, C. Crystal structure of mistletoe lectin I from Viscum album. Biochem.Biophys.Res.Commun., 257:418-424, 1999 Cited by PubMed Abstract: The crystal structure of the ribosome-inactivating protein (RIP) mistletoe lectin I (ML-I) from Viscum album has been solved by molecular replacement techniques. The structure has been refined to a crystallographic R-factor of 24.5% using X-ray diffraction data to 2.8 A resolution. The heterodimeric 63-kDa protein consists of a toxic A subunit which exhibits RNA-glycosidase activity and a galactose-specific lectin B subunit. The overall protein fold is similar to that of ricin from Ricinus communis; however, unlike ricin, ML-I is already medically applied as a component of a commercially available misteltoe extract with immunostimulating potency and for the treatment of human cancer. The three-dimensional structure reported here revealed structural details of this pharmaceutically important protein. The comparison to the structure of ricin gives more insights into the functional mechanism of this protein, provides structural details for further protein engineering studies, and may lead to the development of more effective therapeutic RIPs. PubMed: 10198229DOI: 10.1006/bbrc.1999.0470 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.7 Å) |
Structure validation
Download full validation report